Qiu L - Search Results

1

A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma.

Wang D, Wang J, Hu G, Wang W, Xiao Y, Cai H, Jiang L, Meng L, Yang Y, Zhou X, Hong Z, Yao Z, Xiao M, Chen L, Mao X, Zhu L, Wang J, Qiu L, Li C, Zhou J. Wang D, et al. Among authors: qiu l. Blood. 2021 May 27;137(21):2890-2901. doi: 10.1182/blood.2020008936. Blood. 2021. PMID: 33512480 Free article. Clinical Trial.

2

[The efficacy of thalidomide for multiple myeloma: a clinical analysis of 102 Chinese patients].

Qi PJ, Wang YF, Xu Y, Li YN, Zou DH, Zhao YZ, Xiao ZJ, Qiu LG. Qi PJ, et al. Zhonghua Xue Ye Xue Za Zhi. 2008 Apr;29(4):226-9. Zhonghua Xue Ye Xue Za Zhi. 2008. PMID: 18843974 Chinese.

3

Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.

Zou D, An G, Zhu G, Wang J, Shi L, Meng H, Xu Y, Sui W, Deng S, Zhan F, Qiu L. Zou D, et al. Among authors: qiu l. Biol Blood Marrow Transplant. 2014 Mar;20(3):319-25. doi: 10.1016/j.bbmt.2013.11.022. Epub 2013 Dec 1. Biol Blood Marrow Transplant. 2014. PMID: 24296491 Free article.

4

Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients.

An G, Qin X, Acharya C, Xu Y, Deng S, Shi L, Zang M, Sui W, Yi S, Li Z, Hao M, Feng X, Jin F, Zou D, Qi J, Zhao Y, Tai YT, Wang J, Qiu L. An G, et al. Among authors: qiu l. Ann Hematol. 2015 Feb;94(2):257-64. doi: 10.1007/s00277-014-2211-0. Epub 2014 Sep 18. Ann Hematol. 2015. PMID: 25231928

5

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Corradini P, Chuncharunee S, Lee JJ, Schlossman RL, Shelekhova T, Yong K, Tan D, Numbenjapon T, Cavenagh JD, Hou J, LeBlanc R, Nahi H, Qiu L, Salwender H, Pulini S, Moreau P, Warzocha K, White D, Bladé J, Chen W, de la Rubia J, Gimsing P, Lonial S, Kaufman JL, Ocio EM, Veskovski L, Sohn SK, Wang MC, Lee JH, Einsele H, Sopala M, Corrado C, Bengoudifa BR, Binlich F, Richardson PG. San-Miguel JF, et al. Among authors: qiu l. Lancet Oncol. 2014 Oct;15(11):1195-206. doi: 10.1016/S1470-2045(14)70440-1. Epub 2014 Sep 18. Lancet Oncol. 2014. PMID: 25242045 Clinical Trial.

6

APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.

Tai YT, Acharya C, An G, Moschetta M, Zhong MY, Feng X, Cea M, Cagnetta A, Wen K, van Eenennaam H, van Elsas A, Qiu L, Richardson P, Munshi N, Anderson KC. Tai YT, et al. Among authors: qiu l. Blood. 2016 Jun 23;127(25):3225-36. doi: 10.1182/blood-2016-01-691162. Epub 2016 Apr 28. Blood. 2016. PMID: 27127303 Free PMC article.

7

Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication.

An G, Acharya C, Feng X, Wen K, Zhong M, Zhang L, Munshi NC, Qiu L, Tai YT, Anderson KC. An G, et al. Among authors: qiu l. Blood. 2016 Sep 22;128(12):1590-603. doi: 10.1182/blood-2016-03-707547. Epub 2016 Jul 14. Blood. 2016. PMID: 27418644 Free PMC article.

8

Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma.

Leng Y, Qiu L, Hou J, Zhao Y, Zhang X, Yang S, Xi H, Huang Z, Pan L, Chen W. Leng Y, et al. Among authors: qiu l. Chin J Cancer. 2016 Sep 8;35(1):86. doi: 10.1186/s40880-016-0140-0. Chin J Cancer. 2016. PMID: 27608772 Free PMC article. Clinical Trial.

9

Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors.

Cao Y, Zhu T, Zhang P, Xiao M, Yi S, Yang Y, Li Q, Ling S, Wang Y, Gao L, Zhu L, Wang J, Wang N, Huang L, Zhang P, Zhai Q, Qiu L, Zhou J. Cao Y, et al. Among authors: qiu l. Oncotarget. 2016 Dec 13;7(50):83294-83307. doi: 10.18632/oncotarget.13065. Oncotarget. 2016. PMID: 27825110 Free PMC article.

10

Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China.

Shi Y, Jia B, Xu W, Li W, Liu T, Liu P, Zhao W, Zhang H, Sun X, Yang H, Zhang X, Jin J, Jin Z, Li Z, Qiu L, Dong M, Huang X, Luo Y, Wang X, Wang X, Wu J, Xu J, Yi P, Zhou J, He H, Liu L, Shen J, Tang X, Wang J, Yang J, Zeng Q, Zhang Z, Cai Z, Chen X, Ding K, Hou M, Huang H, Li X, Liang R, Liu Q, Song Y, Su H, Gao Y, Liu L, Luo J, Su L, Sun Z, Tan H, Wang H, Wang J, Wang S, Zhang H, Zhang X, Zhou D, Bai O, Wu G, Zhang L, Zhang Y. Shi Y, et al. Among authors: qiu l. J Hematol Oncol. 2017 Mar 15;10(1):69. doi: 10.1186/s13045-017-0439-6. J Hematol Oncol. 2017. PMID: 28298231 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

6,311 results

Search Page